Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
about
Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesionsAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.The p53-estrogen receptor loop in cancerThe influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assayClinical progress of human papillomavirus genotypes and their persistent infection in subjects with atypical squamous cells of undetermined significance cytology: Statistical and latent Dirichlet allocation analysis.A comparison of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and surface plasmon resonance for genotyping of high-risk human papillomaviruses.Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysisHuman papillomavirus genotypes in cervical intraepithelial neoplasia grade 3Development and evaluation of a PCR and mass spectroscopy (PCR-MS)-based method for quantitative, type-specific detection of human papillomavirusHuman papillomavirus infection in women with and without cervical cancer in Ibadan, NigeriaInference of type-specific HPV transmissibility, progression and clearance rates: a mathematical modelling approachLower cost strategies for triage of human papillomavirus DNA-positive women.Comparison of the DiagCor GenoFlow Human Papillomavirus Array Test and Roche Linear Array HPV Genotyping Test.A cross-sectional study to assess HPV knowledge and HPV vaccine acceptability in MaliHuman papillomavirus testing in the prevention of cervical cancerComparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brushEfficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women.Comparison of Hybribio GenoArray and Roche human papillomavirus (HPV) linear array for HPV genotyping in anal swab samplesInhibitors of differentiation-1 promotes nitrosopyrrolidine-induced transformation of HPV 16-immortalized cervical epithelial cell.Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test.Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance.Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions.Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study.Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix.HPV-DNA testing for cervical cancer precursors: from evidence to clinical practiceConfirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping testComparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage studyHuman papillomavirus (HPV) in atypical squamous cervical cytology: the Invader HPV test as a new screening assay.Genotype distribution of human papillomaviruses in Japanese women with abnormal cervical cytology.The contribution of HPV18 to cervical cancer is underestimated using high-grade CIN as a measure of screening efficiency.High-risk HPV type-specific clearance rates in cervical screening.Human papillomaviral load changes in low-grade squamous intraepithelial lesions of the uterine cervixPreferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The NetherlandsPerceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasiaFive-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.Prophylactic human papillomavirus vaccines: potential for sea change.
P2860
Q24198236-B8B40BF1-2C64-47A5-BAE2-295933777F78Q24607403-F5A154EB-21A4-4E59-B24D-147F1F109350Q26828840-D1F6A1DF-E88C-4C39-9E7D-5CA197397CB8Q27027865-F5F4259E-CC8F-4DCF-B878-5084264304DBQ30409120-77A129A3-471D-4D34-816D-F018D4565128Q33704883-720DC646-380A-4673-B7C9-E7A1009A4997Q33744883-A3C4CB1B-434F-4AEB-B5BE-7ADDA83B5BB4Q33795640-7CEF9A1D-B4F8-4DAE-AFBE-1AE3F576CFF3Q33883532-3E0A3F03-C0F5-4342-8929-5CBDB924AF0DQ33984185-BB6888EC-31F9-445F-B327-B1B4FDA29E56Q34420904-8192EE48-EB7B-4F72-A0CB-AF406C7D4BF1Q34471165-B37F75D4-6CD3-44A0-8DB9-AEA4C905F9AEQ34490267-AF1534C8-26A0-4DAD-AA87-0A9C8898D6FCQ34516596-BFDB61E8-1EC5-462D-9EA3-85EBAE5659A7Q34517952-861AD250-0E3C-4137-ACE3-9739DA33DAE1Q34595075-CB1177E9-D97B-45DF-9F4E-E241B82C6B7AQ34616083-62ADA4C9-A821-4B94-9D16-FEA47FAF3F58Q34719578-72747520-D2D3-4C23-8785-B8ECE58409CBQ34720012-40EA5839-061A-43D9-BC5E-1FC05E5916CDQ34776171-63411E94-AA73-48D5-ABE8-00EA634B06BCQ34959801-F495A8B6-E0CF-4A54-A32E-61888EAEFF75Q34983076-F8F66933-ADB6-42B2-BE5D-776352B53510Q35051556-ED4AD835-1D67-4888-86DB-0ED3C850CEB4Q35073364-38FFC091-F75E-452F-B15D-A8E9956C48F6Q35690441-3F95F6CA-89B2-4F1D-9236-AAF96DC62669Q35757654-E4856F4F-D11D-431D-8782-5DE43F421048Q35810353-20066EE0-5528-4DBF-8B8F-5196F2047091Q35867881-4D068929-2CFD-4902-940C-F01390857663Q36071760-90FD4BBC-E98F-4356-9233-99FC37DF0974Q36314457-55CEA013-55CB-4CC7-B7EF-34B250283570Q36423668-BD89A394-226E-4E4C-AB59-25A4254D04C3Q36497867-F54CC818-5E57-4D8F-B95A-CF0EA259BA45Q36540527-0F895B69-AB8B-4B88-930A-7E34FFA5B3A2Q36610328-C1765FD2-FABD-416A-85B1-D90A54756E49Q36610417-42FE3E39-070B-4CDD-9B0C-2CDCE7D9E690Q36612029-7217463B-07EB-414E-8AE1-4305A9F3D3B9Q36613522-9328661C-FCA5-4B73-A642-E98DCB423C0FQ36677490-4778C3C8-156A-4D21-92F1-07E83916BEB2Q36740209-AE036CFB-D7AE-40E5-AAAA-B79C39FD01B2Q36899064-FFB9E44B-A114-4FD1-9F99-22D123E160F6
P2860
Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Human papillomavirus type 16 i ...... mild cytologic abnormalities.
@en
Human papillomavirus type 16 i ...... mild cytologic abnormalities.
@nl
type
label
Human papillomavirus type 16 i ...... mild cytologic abnormalities.
@en
Human papillomavirus type 16 i ...... mild cytologic abnormalities.
@nl
prefLabel
Human papillomavirus type 16 i ...... mild cytologic abnormalities.
@en
Human papillomavirus type 16 i ...... mild cytologic abnormalities.
@nl
P2860
P356
P1476
Human papillomavirus type 16 i ...... mild cytologic abnormalities.
@en
P2093
Diane Solomon
Philip E Castle
P2860
P304
P356
10.1093/JNCI/DJI186
P407
P577
2005-07-01T00:00:00Z